niacinamide has been researched along with Leucocythaemia in 21 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory extracranial solid tumors and evaluate the tolerability of the solid tumor MTD in children with refractory leukemias." | 9.16 | A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. ( Adamson, PC; Balis, FM; Baruchel, S; Blaney, SM; Burke, M; Fox, E; Glade Bender, J; Ingle, AM; Kim, A; Stempak, D; Weigel, B; Widemann, BC, 2012) |
| "To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia." | 9.15 | Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ( Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011) |
| "By combining in vitro and ex vivo studies, the effect of nelfinavir on leukemia cells and non-malignant, bone marrow-derived tissue cells was analyzed." | 7.76 | The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. ( Brüning, A; Friese, K; Gingelmaier, A; Rahmeh, M, 2010) |
| "Sorafenib pretreatment down-regulated Bcl-xL and abrogated Mcl-1 expression, whereas addition of TRAIL sharply increased Bid activation, conformational change of Bak (ccBak) and Bax (ccBax), and Bax translocation." | 5.34 | The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. ( Almenara, JA; Coe, S; Grant, S; Rosato, RR, 2007) |
| "To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory extracranial solid tumors and evaluate the tolerability of the solid tumor MTD in children with refractory leukemias." | 5.16 | A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. ( Adamson, PC; Balis, FM; Baruchel, S; Blaney, SM; Burke, M; Fox, E; Glade Bender, J; Ingle, AM; Kim, A; Stempak, D; Weigel, B; Widemann, BC, 2012) |
| "To assess the toxicity, pharmacokinetics, and pharmacodynamics of multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in children with relapsed/refractory leukemia." | 5.15 | Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ( Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011) |
| " Here we describe the synthesis of a series of twenty-two trifluoromethyl arylamides based on the known SRPKs inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl)isonicotinamide (SRPIN340) and the evaluation of their antileukemia effects." | 3.85 | Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs). ( Almeida, MR; Barbosa, ÉAA; Barros, MVA; Bressan, GC; de Oliveira, LL; Fietto, JLR; Gonçalves, VHS; Onofre, TS; Pereira, HS; Silva Júnior, A; Siqueira, RP; Teixeira, RR, 2017) |
| "By combining in vitro and ex vivo studies, the effect of nelfinavir on leukemia cells and non-malignant, bone marrow-derived tissue cells was analyzed." | 3.76 | The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. ( Brüning, A; Friese, K; Gingelmaier, A; Rahmeh, M, 2010) |
| "Here, we review recent findings that cancer cell sensitivity to TRAIL is greatly increased when the Bcl-2 family protein Mcl-1 is down-regulated by the Raf/vascular endothelial growth factor kinase inhibitor sorafenib, a Food and Drug Administration-approved cancer drug." | 2.44 | Mcl-1: a gateway to TRAIL sensitization. ( El-Deiry, WS; Kim, SH; Ricci, MS, 2008) |
| "Sorafenib pretreatment down-regulated Bcl-xL and abrogated Mcl-1 expression, whereas addition of TRAIL sharply increased Bid activation, conformational change of Bak (ccBak) and Bax (ccBax), and Bax translocation." | 1.34 | The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. ( Almenara, JA; Coe, S; Grant, S; Rosato, RR, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 11 (52.38) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| ElMokh, O | 1 |
| Matsumoto, S | 1 |
| Biniecka, P | 1 |
| Bellotti, A | 1 |
| Schaeuble, K | 1 |
| Piacente, F | 1 |
| Gallart-Ayala, H | 1 |
| Ivanisevic, J | 1 |
| Stamenkovic, I | 1 |
| Nencioni, A | 2 |
| Nahimana, A | 1 |
| Duchosal, MA | 1 |
| Liu, M | 1 |
| Zhou, P | 1 |
| Li, J | 1 |
| Jiang, Y | 1 |
| Siqueira, RP | 2 |
| Barros, MVA | 1 |
| Barbosa, ÉAA | 1 |
| Onofre, TS | 1 |
| Gonçalves, VHS | 1 |
| Pereira, HS | 1 |
| Silva Júnior, A | 1 |
| de Oliveira, LL | 2 |
| Almeida, MR | 2 |
| Fietto, JLR | 1 |
| Teixeira, RR | 2 |
| Bressan, GC | 2 |
| Musso, O | 1 |
| Beraza, N | 1 |
| Takeuchi, M | 1 |
| Niimi, T | 1 |
| Masumoto, M | 1 |
| Orita, M | 1 |
| Yokota, H | 1 |
| Yamamoto, T | 1 |
| Perova, T | 1 |
| Grandal, I | 1 |
| Nutter, LM | 1 |
| Papp, E | 1 |
| Matei, IR | 1 |
| Beyene, J | 1 |
| Kowalski, PE | 1 |
| Hitzler, JK | 1 |
| Minden, MD | 1 |
| Guidos, CJ | 1 |
| Danska, JS | 1 |
| Cagnetta, A | 1 |
| Caffa, I | 1 |
| Acharya, C | 1 |
| Soncini, D | 1 |
| Acharya, P | 1 |
| Adamia, S | 1 |
| Pierri, I | 1 |
| Bergamaschi, M | 1 |
| Garuti, A | 1 |
| Fraternali, G | 1 |
| Mastracci, L | 1 |
| Provenzani, A | 1 |
| Zucal, C | 1 |
| Damonte, G | 1 |
| Salis, A | 1 |
| Montecucco, F | 1 |
| Patrone, F | 1 |
| Ballestrero, A | 1 |
| Bruzzone, S | 1 |
| Gobbi, M | 1 |
| Cea, M | 1 |
| Barbosa, Éde A | 1 |
| Polêto, MD | 1 |
| Righetto, GL | 1 |
| Seraphim, TV | 1 |
| Salgado, RL | 1 |
| Ferreira, JG | 1 |
| Barros, MV | 1 |
| Laranjeira, AB | 1 |
| Júnior, AS | 1 |
| Fietto, JL | 1 |
| Kobarg, J | 1 |
| de Oliveira, EB | 1 |
| Borges, JC | 1 |
| Yunes, JA | 1 |
| Grunwald, MR | 1 |
| McDonnell, MH | 1 |
| Induru, R | 1 |
| Gerber, JM | 1 |
| Brüning, A | 1 |
| Rahmeh, M | 1 |
| Gingelmaier, A | 1 |
| Friese, K | 1 |
| Inaba, H | 1 |
| Rubnitz, JE | 1 |
| Coustan-Smith, E | 1 |
| Li, L | 1 |
| Furmanski, BD | 1 |
| Mascara, GP | 1 |
| Heym, KM | 1 |
| Christensen, R | 1 |
| Onciu, M | 1 |
| Shurtleff, SA | 1 |
| Pounds, SB | 1 |
| Pui, CH | 1 |
| Ribeiro, RC | 1 |
| Campana, D | 1 |
| Baker, SD | 1 |
| Wellbrock, J | 1 |
| Fiedler, W | 1 |
| Widemann, BC | 1 |
| Kim, A | 1 |
| Fox, E | 1 |
| Baruchel, S | 1 |
| Adamson, PC | 1 |
| Ingle, AM | 1 |
| Glade Bender, J | 1 |
| Burke, M | 1 |
| Weigel, B | 1 |
| Stempak, D | 1 |
| Balis, FM | 1 |
| Blaney, SM | 1 |
| OETTGEN, HF | 1 |
| PURPLE, JR | 1 |
| COLEY, VC | 1 |
| KRAKOFF, IH | 1 |
| BURCHENAL, JH | 1 |
| IVANOVA, VD | 1 |
| RAUSHENBAKH, MO | 1 |
| EHRHART, H | 1 |
| SCHEFFEL, G | 1 |
| Rahmani, M | 1 |
| Davis, EM | 1 |
| Bauer, C | 1 |
| Dent, P | 1 |
| Grant, S | 2 |
| Rosato, RR | 1 |
| Almenara, JA | 1 |
| Coe, S | 1 |
| Kim, SH | 1 |
| Ricci, MS | 1 |
| El-Deiry, WS | 1 |
| Olsson, A | 1 |
| Olofsson, T | 1 |
| Pero, RW | 1 |
| Yamadori, I | 1 |
| Yoshino, T | 1 |
| Kondo, E | 1 |
| Cao, L | 1 |
| Akagi, T | 1 |
| Matsuo, Y | 1 |
| Minowada, J | 1 |
3 reviews available for niacinamide and Leucocythaemia
| Article | Year |
|---|---|
Cutaneous manifestations in leukemia patients.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomyco | 2016 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical | 2011 |
Mcl-1: a gateway to TRAIL sensitization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Down-Regulation; Drug Resistance, | 2008 |
2 trials available for niacinamide and Leucocythaemia
| Article | Year |
|---|---|
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; | 2011 |
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Leukemia; Male; Neoplasm | 2012 |
16 other studies available for niacinamide and Leucocythaemia
| Article | Year |
|---|---|
Gut microbiota severely hampers the efficacy of NAD-lowering therapy in leukemia.
Topics: Cell Line, Tumor; Cytokines; Gastrointestinal Microbiome; Humans; Leukemia; NAD; Neoplasms; Niacinam | 2022 |
Nicotinamide Inhibits Glycolysis of HL-60 Cells by Modulating Sirtuin 1 (SIRT1)/Peroxisome Proliferator-Activated Receptor γ Coactivator 1α (PGC-1α)/Hypoxia-Inducible Factor-2α (HIF2α) Signaling Pathway.
Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Gene Expression Regulation; HL-60 Cells; Hu | 2020 |
Trifluoromethyl arylamides with antileukemia effect and intracellular inhibitory activity over serine/arginine-rich protein kinases (SRPKs).
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Death; Cell Line, Tumor; Cell Prolife | 2017 |
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.
Topics: Carcinoma, Hepatocellular; Humans; Leukemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sor | 2019 |
Discovery of a novel nicotinamide phosphoribosyl transferase (NAMPT) inhibitor via in silico screening.
Topics: Animals; Antineoplastic Agents; Apoptosis; Computer Simulation; Drug Discovery; Enzyme Inhibitors; H | 2014 |
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Topics: Administration, Oral; Adult; Aminopyridines; Animals; Cell Proliferation; Cell Survival; Child; Fema | 2014 |
APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells.
Topics: Acrylamides; Adenosine Triphosphate; Aged; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Tr | 2015 |
Potential Antileukemia Effect and Structural Analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340).
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Blotting, Western; Cell Survival; Cells, Cultured; | 2015 |
The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.
Topics: Apoptosis; Benzenesulfonates; Bone Marrow Cells; Caspase 8; CDC2 Protein Kinase; Cell Cycle; Cell Li | 2010 |
POTENTIATION OF THE ANTI-LEUKEMIC EFFECTS OF 2-AMINOTHIADIAZOLE BY ISONICOTINAMIDE AND DERIVATIVES.
Topics: Amides; Animals; Antineoplastic Agents; Isonicotinic Acids; Leukemia; Leukemia L1210; Leukemia, Expe | 1964 |
[TRYPTOPHAN METABOLISM IN LEUKEMIA].
Topics: Anemia; Anemia, Aplastic; Chromatography; Drug Therapy; Hodgkin Disease; Humans; Indoles; Leukemia; | 1964 |
[STUDIES ON LEUKOCYTE METABOLISM. NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD) CONTENT OF NORMAL AND LEUKEMIC LEUKOCYTES IN MAN. II].
Topics: Adenine; Blood Cell Count; Blood Chemical Analysis; Erythrocytes; Humans; Leukemia; Leukemia, Lympho | 1965 |
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspase 7; Caspase 9; Caspases; Cell | 2005 |
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protei | 2007 |
Specific binding and uptake of extracellular nicotinamide in human leukemic K-562 cells.
Topics: Binding, Competitive; Carbon Radioisotopes; Cell Membrane; Cell Nucleus; Humans; Leukemia; NAD; Niac | 1993 |
Comparison of two methods of staining apoptotic cells of leukemia cell lines. Terminal deoxynucleotidyl transferase and DNA polymerase I reactions.
Topics: Antibodies, Monoclonal; Apoptosis; Benzamides; Cell Nucleus; Coloring Agents; Cytoplasm; Deoxyribonu | 1998 |